AIDA
The Anti-Interleukin-1 in Diabetes Action Trial
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes.
Sites Include:
- Aalborg Hospital (Aalborg, Denmark)
- Aarhus University Hospital (Aarhus, Denmark)
- Bispebjerg University Hospital (Copenhagen, Denmark)
- German Diabetes Centre (Dusseldorf, Germany)
- Hospital Arnau de Vilanova (Lleida, Spain)
- Hospital Universitario Insular de Gran Canaria (Las Palmas de GC, Spain)
- Hospital de Cruces (Barakaldo, Spain)
- Hospital Santa Creu i Sant Pau (Barcelona, Spain)
- Leiden University Medical Center (Leiden, Netherlands)
- Medical University of Bialystok (Bialystok, Poland)
- Munich University of Technology (Munich, Germany)
- Hillerod Hospital (Hillerod, Denmark)
- Steno Diabetes Center (Gentofte, Denmark)
- Ulm University (Ulm/Donau, Germany)
- University Campus Bio-Medico (Rome, Italy)
- University Hospital Basel (Basel, Switzerland)
- University Hospital Frankfurt am Main (Frankfurt, Germany)
On the Web: http://www.aidastudy.org
JDRF: 8-2002-175